Schenk B E, Kuipers E J, Klinkenberg-Knol E C, Bloemena E, Nelis G F, Festen H P, Jansen E H, Biemond I, Lamers C B, Meuwissen S G
Department of Gastroenterology, Free University Hospital, Amsterdam, The Netherlands.
Aliment Pharmacol Ther. 1998 Jul;12(7):605-12. doi: 10.1046/j.1365-2036.1998.00349.x.
elucidate the mechanisms that lead to severe hypergastrinaemia during long-term omeprazole therapy for gastro-oesophageal reflux disease (GERD).
A total of 26 GERD patients were studied during omeprazole maintenance therapy. Twelve patients with severe hypergastrinaemia (gastrin > 400 ng/L) were compared with 14 control patients (gastrin < 300 ng/L). Helicobacter pylori serology and a laboratory screen were obtained in all patients. Gastric emptying was scored by the evidence of food remnants upon endoscopy 12 h after a standardized meal. Gastric antrum and corpus biopsies were analysed for histological parameters, as well as somatostatin and gastrin concentrations. All patients underwent a meal-stimulated gastrin test and the hypergastrinaemia patients also underwent a vagal nerve integrity assessment by pancreatic polypeptide testing (PPT).
Severe hypergastrinaemia patients had a longer duration of treatment (80 vs. 55 months; P = 0.047) and were characterized by a higher prevalence of H. pylori infection (9/12 vs. 2/14, P = 0.004), corpus mucosal inflammation and atrophic gastritis (P < 0.04). This was reflected in lower serum pepsinogen A concentrations (mean +/- S.E.M. 53.6 +/- 17.9 vs. 137 +/- 16.0 mg/L, P = 0.03), pepsinogen A/C ratio (1.8 +/- 0.3 vs. 4.1 +/- 0.6, P = 0.005) and mucosal somatostatin concentrations (2.75 +/- 0.60 vs. 4.48 +/- 1.08 mg/g protein, P = 0.038). Two patients in the hypergastrinaemia group had signs of delayed gastric emptying, but none in the normogastrinaemia group did (P = N.S.). In addition, both groups had a normal meal-stimulated gastrin response.
Severe hypergastrinaemia during omeprazole maintenance therapy for GERD is associated with the duration of therapy and H. pylori infection, but not with abnormalities of gastric emptying or vagal nerve integrity.
阐明在长期使用奥美拉唑治疗胃食管反流病(GERD)期间导致严重高胃泌素血症的机制。
共对26例GERD患者进行了奥美拉唑维持治疗期间的研究。将12例严重高胃泌素血症患者(胃泌素>400 ng/L)与14例对照患者(胃泌素<300 ng/L)进行比较。所有患者均进行了幽门螺杆菌血清学检测和实验室筛查。通过标准化餐后12小时内镜检查时食物残渣的情况对胃排空进行评分。对胃窦和胃体活检组织进行组织学参数以及生长抑素和胃泌素浓度分析。所有患者均接受了餐刺激胃泌素试验,高胃泌素血症患者还通过胰多肽试验(PPT)进行了迷走神经完整性评估。
严重高胃泌素血症患者的治疗时间更长(80个月对55个月;P = 0.047),其特征为幽门螺杆菌感染患病率更高(9/12对2/14,P = 0.004)、胃体黏膜炎症和萎缩性胃炎(P < 0.04)。这反映在较低的血清胃蛋白酶原A浓度(均值±标准误 53.6±17.9对137±16.0 mg/L,P = 0.03)、胃蛋白酶原A/C比值(1.8±0.3对4.1±0.6,P = 0.005)和黏膜生长抑素浓度(2.75±0.60对4.48±1.08 mg/g蛋白质,P = 0.038)。高胃泌素血症组有2例患者出现胃排空延迟迹象,而正常胃泌素血症组无此情况(P =无显著差异)。此外,两组的餐刺激胃泌素反应均正常。
GERD患者奥美拉唑维持治疗期间的严重高胃泌素血症与治疗持续时间和幽门螺杆菌感染有关,但与胃排空异常或迷走神经完整性无关。